leptin has been researched along with Musculoskeletal-Diseases* in 4 studies
2 review(s) available for leptin and Musculoskeletal-Diseases
Article | Year |
---|---|
[Uncommon lipodystrophic syndromes].
Topics: Acro-Osteolysis; Adipose Tissue; Aging, Premature; Body Composition; Cardiovascular System; Combined Modality Therapy; Diabetes Mellitus; Diet, Carbohydrate-Restricted; Diet, Fat-Restricted; Erythema Nodosum; Fingers; Genes, Dominant; Humans; Hypoglycemic Agents; Insulin; Leptin; Lipodystrophy; Lipodystrophy, Familial Partial; Mandible; Metformin; Musculoskeletal Diseases; Phenotype; Recombinant Proteins; Surgery, Plastic; Werner Syndrome | 2015 |
Comorbidities of obesity.
Obesity, especially visceral adiposity, is associated with morbidity and mortality through endocrine and mechanical processes. Clinical manifestations due to effects of obesity on the cardiovascular, respiratory, gastrointestinal, musculoskeletal, immune, and integumentary systems have been described. Further studies are needed to understand the pathologic processes underlying these clinical manifestations to improve disease prevention. Topics: Adipocytes; Adiponectin; Adiposity; Cardiovascular Diseases; Energy Metabolism; Exercise; Gastrointestinal Diseases; Humans; Insulin Resistance; Intra-Abdominal Fat; Leptin; Musculoskeletal Diseases; Neoplasms; Obesity; Respiratory Tract Diseases | 2009 |
2 other study(ies) available for leptin and Musculoskeletal-Diseases
Article | Year |
---|---|
[Musculoskeletal relevance of obesity: a new approach to an old topic].
Authors discuss the musculoskeletal aspects of obesity by applying a novel approach. Biochemical changes associated with obesity and especially metabolic syndrome, may have a great impact on the function of bones, joints and muscles. Therefore we need a new view and new strategies in rheumatic diseases. Obesity-associated metabolic changes should be considered during the progress of as well as the selection of treatment in inflammatory rheumatic diseases. Individualised treatment is necessary due to associated comorbidities as well. Orv Hetil. 2019; 160(44): 1727-1734.. Absztrakt: A szerzők az elhízás mozgásszervi vonatkozásait új megközelítésben, elsősorban annak metabolikus hatásait kiemelve ismertetik. Az elhízással és különösen a metabolikus szindrómával járó biokémiai változások megváltoztatják a csont, az ízületi struktúrák és az izomzat működését. Ezek alapján szemléletváltozás szükséges bizonyos kórképekben az eddig kialakult nézetekben. A gyulladásos reumatológiai betegségek lefolyásának súlyosságában és az alkalmazott kezelések megválasztásában is figyelembe kell venni az elhízással járó anyagcsere-változásokat. A társuló komorbiditások miatt a személyre szabott kezelés fontossága kiemelt jelentőségű. Orv Hetil. 2019; 160(44): 1727–1734. Topics: Adipokines; Arthritis; Humans; Joint Diseases; Leptin; Metabolic Syndrome; Musculoskeletal Diseases; Obesity; Osteoarthritis; Rheumatic Diseases | 2019 |
Adipokines as predictors of recovery from upper extremity soft tissue disorders.
To study the associations of adipokines with recovery from upper extremity soft tissue disorders (UESTDs) and to explore whether overweight or obesity modify these associations.. In this follow-up study, patients seeking medical advice due to incipient upper extremity symptoms with symptom duration <1 month were included (n = 163). The outcome of the study was full or substantial recovery from UESTDs, assessed at 2, 8 and 12 weeks of follow-up. We studied the associations of four adipokines (leptin, adiponectin, resistin and visfatin) with recovery using the generalized estimating equation.. Of the study population, 27.5% reported full or substantial recovery at the 8-week follow-up and 32% at 12 weeks. Higher levels of resistin [odds ratio (OR) = 1.58, 95% CI 1.18, 2.11 for 1 s.d. increase] and visfatin (OR = 1.29, 95% CI 0.94, 1.78 for 1 s.d. increase) at baseline predicted a higher recovery rate at the 8-week follow-up. Moreover, higher levels of leptin predicted a lower rate of recovery (OR = 0.73, 95% CI 0.51, 1.02 for 1 s.d. increase). Adipokines did not predict recovery at 12 weeks. In subgroup analyses, high levels of resistin and visfatin at baseline predicted a higher recovery rate during follow-up in non-overweight patients.. The adipokines resistin and visfatin predicted recovery from UESTDs and the associations may be related to stimulation of anti-inflammatory response mechanisms. A higher level of leptin may prevent recovery from UESTDs. Topics: Adipokines; Adult; Biomarkers; Cytokines; Female; Follow-Up Studies; Humans; Leptin; Male; Middle Aged; Musculoskeletal Diseases; Nicotinamide Phosphoribosyltransferase; Obesity; Prognosis; Resistin; Tendinopathy; Upper Extremity | 2014 |